Kenya is one of nine African countries selected for the initial rollout of lenacapavir (LEN), a new injectable drug for human ...

The owner of the United States' largest pharmacy benefit manager (PBM) is declining to cover Gilead Sciences’ long-acting HIV ...

Advocates for HIV prevention are calling a newly approved injectable medication a major step in eliminating the spread of the ...

Lenacapavir’s capsid inhibition is relatively less understood compared to mechanisms of other approved approaches in HIV. However, the capsid protein is essential for viral entry and hence ...

Last year, studies suggested that lenacapavir, already used to treat people with HIV, was nearly 100% effective in stopping transmission in both women and men.

Gilead's Q2 earnings beat and raised 2025 outlook lift shares 7.3%, fueled by HIV gains, Trodelvy strength, and new PrEP ...

Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 clinical trial has shown.

Lenacapavir is given in two injections that have to be delivered subcutaneously, something that “takes training and time” to learn, National Institute of Allergy and Infectious Diseases ...

Gilead Sciences is a fantastic company that's revolutionized the treatment of numerous diseases. But click here to read why ...

Lenacapavir showed a 96% reduction in HIV infections, outperforming daily F/TDF in the PURPOSE 2 trial. The trial included a diverse global population, with 67% non-White participants, enhancing ...

“Lenacapavir represents a major scientific advance — it’s the first long-acting injectable HIV prevention strategy that requires dosing just twice a year,” according to Paul E. Sax, MD ...

Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV – Patient-Reported Outcomes From the CAPELLA Trial Align With the Demonstrated Safety ...